$BDTX

Black Diamond Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$4.03 ▲0.499%

Extented Hours

VOLUME

227,635

DAY RANGE

3.875 - 4.01

52 WEEK

1.46 - 10.47

Join Discuss about BDTX with like-minded investors

profile
@maletone #StockTraders.NET
recently

been slacking missed $BDTX in pre

148 Replies 14 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

$BDTX nice wash

146 Replies 13 👍 6 🔥

profile
@maletone #StockTraders.NET
recently

$BDTX wants to wash

133 Replies 14 👍 10 🔥

profile
@maletone #StockTraders.NET
recently

watching $BDTX

140 Replies 6 👍 9 🔥

profile
@singletary #StockTraders.NET
recently

$bdtx $5 reject

61 Replies 12 👍 7 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

$BDTX was a beautiful fader

103 Replies 14 👍 13 🔥

profile
@dros #droscrew
recently

+Initiations 1/7: $ACCD $AIRC $ARAY $ARCT $AWK $BDTX $CHTR $CVLB $DADA $EVH $INCY $INOV $KNOP $MGTA $NOG $NTST $ORTX $TDOC $TLMD $VEEV . -Initiations 1/7: $FMCC

128 Replies 10 👍 11 🔥

Key Metrics

Market Cap

142.45 M

Beta

1.29

Avg. Volume

163.21 K

Shares Outstanding

36.34 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-08

Next Dividend Date

Company Information

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company's proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine.

Website:

HQ: ,

Related News